These results suggest that cancers with high hCtr1 expression have a better response to Pt-based drugs, suggesting that transcriptional upregulation of hCtr1 expression by Cu-lowering agents can be an attractive strategy for improving chemosensitivity to Pt drugs with the following considerations. The gene discussed is SLC31A1; the disease is cancer.